Literature DB >> 27654060

Precise Targeting of Liver Tumor Using Glycol Chitosan Nanoparticles: Mechanisms, Key Factors, and Their Implications.

Jin Hee Na1,2,3, Heebeom Koo4, Sangmin Lee2,3, Seung Jin Han1, Kyung Eun Lee5, Sunjin Kim6, Haeshin Lee6, Seulki Lee2,3, Kuiwon Choi7, Ick Chan Kwon1,8, Kwangmeyung Kim1.   

Abstract

Herein, we elucidated the mechanisms and key factors for the tumor-targeting ability of nanoparticles that presented high targeting efficiency for liver tumor. We used several different nanoparticles with sizes of 200-300 nm, including liposome nanoparticles (LNPs), polystyrene nanoparticles (PNPs) and glycol chitosan-5β-cholanic acid nanoparticles (CNPs). Their sizes are suitable for the enhanced permeation and retention (EPR) effect in literature. Different in vitro characteristics, such as the particle structure, stability, and bioinertness, were carefully analyzed with and without serum proteins. Also, pH-dependent tumor cell uptakes of nanoparticles were studied using fluorescence microscopy. Importantly, CNPs had sufficient stability and bioinertness to maintain their nanoparticle structure in the bloodstream, and they also presented prolonged circulation time in the body (blood circulation half-life T1/2 = about 12.2 h), compared to the control nanoparticles. Finally, employing liver tumor bearing mice, we also observed that CNPs had excellent liver tumor targeting ability in vivo, while LNPs and PNPs demonstrated lower tumor-targeting efficiency due to the nonspecific accumulation in normal liver tissue. Liver tumor models were produced by laparotomy and direct injection of HT29 tumor cells into the left lobe of the liver of athymic nude mice. This study provides valuable information concerning the key factors for the tumor-targeting ability of nanoparticles such as stability, bioinertness, and rapid cellular uptake at targeted tumor tissues.

Entities:  

Keywords:  biodistribution; liver tumor; nanoparticles; stability; tumor targeting

Mesh:

Substances:

Year:  2016        PMID: 27654060     DOI: 10.1021/acs.molpharmaceut.6b00507

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  8 in total

1.  Functional Peptide Nanofibers with Unique Tumor Targeting and Enzyme-Induced Local Retention Properties.

Authors:  Vanessa Bellat; Richard Ting; Teresa L Southard; Linda Vahdat; Henrik Molina; Joseph Fernandez; Omer Aras; Tracy Stokol; Benedict Law
Journal:  Adv Funct Mater       Date:  2018-09-14       Impact factor: 18.808

2.  Combination of KRAS gene silencing and PI3K inhibition for ovarian cancer treatment.

Authors:  Min Ju Kim; So Jin Lee; Ju Hee Ryu; Sun Hwa Kim; Ick Chan Kwon; Thomas M Roberts
Journal:  J Control Release       Date:  2019-12-12       Impact factor: 9.776

3.  Deep tissue penetration of nanoparticles using pulsed-high intensity focused ultrasound.

Authors:  Dong Gil You; Hong Yeol Yoon; Sangmin Jeon; Wooram Um; Sejin Son; Jae Hyung Park; Ick Chan Kwon; Kwangmeyung Kim
Journal:  Nano Converg       Date:  2017-11-08

Review 4.  Multicomponent, Tumor-Homing Chitosan Nanoparticles for Cancer Imaging and Therapy.

Authors:  Jaehong Key; Kyeongsoon Park
Journal:  Int J Mol Sci       Date:  2017-03-08       Impact factor: 5.923

Review 5.  Chitosan Nanoparticles for Therapy and Theranostics of Hepatocellular Carcinoma (HCC) and Liver-Targeting.

Authors:  Maria Cristina Bonferoni; Elisabetta Gavini; Giovanna Rassu; Marcello Maestri; Paolo Giunchedi
Journal:  Nanomaterials (Basel)       Date:  2020-04-30       Impact factor: 5.076

6.  Physiologically stable F127-GO supramolecular hydrogel with sustained drug release characteristic for chemotherapy and photothermal therapy.

Authors:  Bingxia Li; Luna Zhang; Zichen Zhang; Ruoqing Gao; Hongmei Li; Zhipeng Dong; Qiyan Wang; Qingfa Zhou; Yue Wang
Journal:  RSC Adv       Date:  2018-01-05       Impact factor: 3.361

Review 7.  Glycol Chitosan: A Water-Soluble Polymer for Cell Imaging and Drug Delivery.

Authors:  Fengming Lin; Hao-Ran Jia; Fu-Gen Wu
Journal:  Molecules       Date:  2019-11-29       Impact factor: 4.411

Review 8.  The Evaluation of Drug Delivery Nanocarrier Development and Pharmacological Briefing for Metabolic-Associated Fatty Liver Disease (MAFLD): An Update.

Authors:  Reem Abou Assi; Ibrahim M Abdulbaqi; Chan Siok Yee
Journal:  Pharmaceuticals (Basel)       Date:  2021-03-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.